1916701D.HK

Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials

Retrieved on: 
星期二, 十二月 6, 2022
Best practice, Gene, AU, Aerospace Journalist of the Year Awards, Cros, Data management, Frost, Drug development, NDA, Research, Cell, US FDA, Risk management, Pharmaceutical industry, Fine chemical, IND

SYDNEY, AU, Dec 6, 2022 - (ACN Newswire) - Novotech, the leading Asia Pacific biotech specialist CRO, has been awarded the Frost & Sullivan Company of the Year Award 2022 for Best Practices in the Asia-Pacific contract research organization industry.

Key Points: 
  • SYDNEY, AU, Dec 6, 2022 - (ACN Newswire) - Novotech, the leading Asia Pacific biotech specialist CRO, has been awarded the Frost & Sullivan Company of the Year Award 2022 for Best Practices in the Asia-Pacific contract research organization industry.
  • Novotech has been a recipient of the Frost & Sullivan Asia Pacific Best Practices awards since 2006.
  • Frost & Sullivan said: "Our approach involves the deployment of best practices and strategic analytics across a value chain.
  • Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US.

Novotech Chairs BioCentury Summit Workshop on How to Build and Finance an East-West MRCT Strategy

Retrieved on: 
星期五, 十一月 11, 2022
Clinical trial, FDi Magazine, US FDA, Gene, Plasma protein binding, Ownership, Cell, NDA, CRO, Marketing, MAH, Research, CTA, FIH, Drug development, NMPA, Cros, Pharmaceutical industry, Fine chemical, IND

Novotech has significant real-world experience in East-West MRCT strategy after more than 2 decades managing clinical research programs for biotechs across Asia Pacific and the US.

Key Points: 
  • Novotech has significant real-world experience in East-West MRCT strategy after more than 2 decades managing clinical research programs for biotechs across Asia Pacific and the US.
  • Commenting on Novotech's experience, Chief Commercial Officer Barry Murphy said the right drug development pathway supports investor attraction and a successful clinical program.
  • Strategies for an East-West MRCT include:
    - Companies should engage with the US FDA and NMPA early to confirm guidance on their clinical roadmap.
  • Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases.